Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Odonate Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ODT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ODT exceeded the US Pharmaceuticals industry which returned -6.9% over the past year.
Return vs Market: ODT exceeded the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Odonate Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StOdonate Therapeutics (NASDAQ:ODT) Is In A Good Position To Deliver On Growth Plans
2 months ago | Simply Wall StWho Has Been Buying Odonate Therapeutics, Inc. (NASDAQ:ODT) Shares?
3 months ago | Simply Wall StHow Does Odonate Therapeutics, Inc. (NASDAQ:ODT) Affect Your Portfolio Volatility?
Is Odonate Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ODT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ODT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ODT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ODT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ODT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ODT is overvalued based on its PB Ratio (5.4x) compared to the US Pharmaceuticals industry average (2.4x).
How is Odonate Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ODT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ODT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ODT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ODT's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ODT's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ODT's Return on Equity is forecast to be high in 3 years time
How has Odonate Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ODT is currently unprofitable.
Growing Profit Margin: ODT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ODT is unprofitable, and losses have increased over the past 5 years at a rate of -66.2% per year.
Accelerating Growth: Unable to compare ODT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ODT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: ODT has a negative Return on Equity (-68.9%), as it is currently unprofitable.
How is Odonate Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ODT's short term assets ($183.9M) exceed its short term liabilities ($24.8M).
Long Term Liabilities: ODT's short term assets ($183.9M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: ODT is debt free.
Reducing Debt: ODT has not had any debt for past 5 years.
Inventory Level: ODT has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ODT's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ODT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ODT has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -68.7% each year.
What is Odonate Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ODT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ODT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ODT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ODT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ODT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Tang (52yo)
Mr. Kevin C. Tang has been the Chairman and Chief Executive Officer at Odonate Therapeutics, Inc. since 2013. Mr. Tang has experience evaluating, creating and building biotechnology companies that are focu ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD1.00) is below average for companies of similar size in the US market ($USD3.17M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
|Chairman & CEO||7.25yrs||US$1.00||no data|
|Chief Operating Officer||1.42yrs||US$1.53m||0.0077% $62.4k|
|Chief Medical Officer||2.58yrs||US$1.98m||0.0057% $46.2k|
|CFO & Principal Accounting Officer||1.42yrs||no data||0.0045% $36.8k|
|Vice President of Technical Operations||3.67yrs||no data||no data|
|Chief Scientific Officer||1.42yrs||no data||no data|
|Chief Development Officer||3.5yrs||no data||no data|
Experienced Management: ODT's management team is considered experienced (2.6 years average tenure).
|Chairman & CEO||7.25yrs||US$1.00||no data|
|Independent Director||1.33yrs||US$359.39k||no data|
|Independent Director||3.33yrs||no data||2.01% $16.3m|
|Independent Director||2.75yrs||US$384.39k||no data|
Experienced Board: ODT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.
Odonate Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Odonate Therapeutics, Inc.
- Ticker: ODT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$809.915m
- Shares outstanding: 32.06m
- Website: https://www.odonate.com
Number of Employees
- Odonate Therapeutics, Inc.
- 4747 Executive Drive
- Suite 510
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4OD||MUN (Boerse Muenchen)||Yes||Common Stock||DE||EUR||Dec 2017|
|ODT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Dec 2017|
|4OD||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2017|
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 04:14|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.